Cargando…

Contribution of Auger/conversion electrons to renal side effects after radionuclide therapy: preclinical comparison of (161)Tb-folate and (177)Lu-folate

BACKGROUND: The radiolanthanide (161)Tb has, in recent years, attracted increasing interest due to its favorable characteristics for medical application. (161)Tb exhibits similar properties to the widely-used therapeutic radionuclide (177)Lu. In contrast to (177)Lu, (161)Tb yields a significant numb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Haller, Stephanie, Pellegrini, Giovanni, Vermeulen, Christiaan, van der Meulen, Nicholas P., Köster, Ulli, Bernhardt, Peter, Schibli, Roger, Müller, Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747949/ https://www.ncbi.nlm.nih.gov/pubmed/26860295 http://dx.doi.org/10.1186/s13550-016-0171-1

Ejemplares similares

Production and characterization of no-carrier-added (161)Tb as an alternative to the clinically-applied (177)Lu for radionuclide therapy
por: Gracheva, Nadezda, et al.
Publicado: (2019)

Simultaneous Visualization of (161)Tb- and (177)Lu-Labeled Somatostatin Analogues Using Dual-Isotope SPECT Imaging
por: Borgna, Francesca, et al.
Publicado: (2021)

Promising potential of [(177)Lu]Lu-DOTA-folate to enhance tumor response to immunotherapy—a preclinical study using a syngeneic breast cancer model
por: Guzik, Patrycja, et al.
Publicado: (2020)

Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
por: Müller, Cristina, et al.
Publicado: (2019)

Therapeutic Potential of (47)Sc in Comparison to (177)Lu and (90)Y: Preclinical Investigations
por: Siwowska, Klaudia, et al.
Publicado: (2019)

Prospects in Folate Receptor-Targeted Radionuclide Therapy
por: Müller, Cristina, et al.
Publicado: (2013)

(161)Tb-DOTATOC Production Using a Fully Automated Disposable Cassette System: A First Step Toward the Introduction of (161)Tb into the Clinic
por: Favaretto, Chiara, et al.
Publicado: (2023)

Radiation doses from (161)Tb and (177)Lu in single tumour cells and micrometastases
por: Alcocer-Ávila, Mario E., et al.
Publicado: (2020)

Folate Receptor Targeted Alpha-Therapy Using Terbium-149
por: Müller, Cristina, et al.
Publicado: (2014)

Folate Receptor Targeted Alpha-Therapy Using Terbium-149
por: Müller, Cristina, et al.
Publicado: (2014)

Preclinical evaluation of 5-methyltetrahydrofolate-based radioconjugates—new perspectives for folate receptor–targeted radionuclide therapy
por: Guzik, Patrycja, et al.
Publicado: (2020)

Alpha-PET for Prostate Cancer: Preclinical investigation using 149Tb-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2019)

Alpha-PET for Prostate Cancer: Preclinical investigation using (149)Tb-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2019)

Preclinical in vivo application of $^{152}$Tb-DOTANOC: a radiolanthanide for PET imaging
por: Müller, Cristina, et al.
Publicado: (2016)

Preclinical in vivo application of (152)Tb-DOTANOC: a radiolanthanide for PET imaging
por: Müller, Cristina, et al.
Publicado: (2016)

A Step-by-Step Guide for the Novel Radiometal Production for Medical Applications: Case Studies with (68)Ga, (44)Sc, (177)Lu and (161)Tb
por: Talip, Zeynep, et al.
Publicado: (2020)

Preclinical investigations using [(177)Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer
por: Tschan, Viviane J., et al.
Publicado: (2022)

Feasibility of simplifying renal dosimetry in (177)Lu peptide receptor radionuclide therapy
por: Sundlöv, Anna, et al.
Publicado: (2018)

Dosimetric Analysis of the Short-Ranged Particle Emitter (161)Tb for Radionuclide Therapy of Metastatic Prostate Cancer
por: Bernhardt, Peter, et al.
Publicado: (2021)

Practical kidney dosimetry in peptide receptor radionuclide therapy using [(177)Lu]Lu-DOTATOC and [(177)Lu]Lu-DOTATATE with focus on uncertainty estimates
por: Staanum, Peter Frøhlich, et al.
Publicado: (2021)

Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection
por: Verburg, Frederik A., et al.
Publicado: (2023)

Deadtime effects in quantification of (177)Lu activity for radionuclide therapy
por: Uribe, Carlos F., et al.
Publicado: (2018)

Radionuclide generator-based production of therapeutic (177)Lu from its long-lived isomer (177m)Lu
por: Bhardwaj, Rupali, et al.
Publicado: (2019)

Preclinical investigations and first-in-human application of $^{152}$Tb-PSMA-617 for PET/CT imaging of prostate cancer
por: Müller, Cristina, et al.
Publicado: (2019)

Preclinical investigations and first-in-human application of (152)Tb-PSMA-617 for PET/CT imaging of prostate cancer
por: Müller, Cristina, et al.
Publicado: (2019)

Fluorescent, Plasmonic, and Radiotherapeutic Properties of the (177)Lu–Dendrimer-AuNP–Folate–Bombesin Nanoprobe Located Inside Cancer Cells
por: Mendoza-Nava, Héctor, et al.
Publicado: (2017)

Establishment of a clinical SPECT/CT protocol for imaging of (161)Tb
por: Marin, I., et al.
Publicado: (2020)

Cure of Disseminated Human Lymphoma with [(177)Lu]Lu-Ofatumumab in a Preclinical Model
por: Shim, Kyuhwan, et al.
Publicado: (2023)

Targeted Radionuclide Therapy with A (177)Lu-labeled Anti-HER2 Nanobody
por: D'Huyvetter, Matthias, et al.
Publicado: (2014)

In Vitro comparison of (213)Bi- and (177)Lu-radiation for peptide receptor radionuclide therapy
por: Chan, Ho Sze, et al.
Publicado: (2017)

Simplified dosimetry for kidneys and tumors in (177)Lu-labeled peptide receptor radionuclide therapy
por: Ardenfors, Oscar, et al.
Publicado: (2022)

Preclinical Efficacy of a PARP-1 Targeted Auger-Emitting Radionuclide in Prostate Cancer
por: Sreekumar, Sreeja, et al.
Publicado: (2023)

Combination of terbium-161 with somatostatin receptor antagonists—a potential paradigm shift for the treatment of neuroendocrine neoplasms
por: Borgna, Francesca, et al.
Publicado: (2021)

(44)Sc-PSMA-617 for radiotheragnostics in tandem with (177)Lu-PSMA-617—preclinical investigations in comparison with (68)Ga-PSMA-11 and (68)Ga-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2017)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

First preclinical evaluation of [(225)Ac]Ac-DOTA-JR11 and comparison with [(177)Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs
por: Handula, Maryana, et al.
Publicado: (2023)

PEGylation, increasing specific activity and multiple dosing as strategies to improve the risk-benefit profile of targeted radionuclide therapy with (177)Lu-DOTA-bombesin analogues
por: Däpp, Simone, et al.
Publicado: (2012)

Can the peptide receptor radionuclide therapy [(177)Lu]Lu-DOTA-TATE provide a net benefit for NET patients?
por: Caplin, Martyn E.
Publicado: (2021)

Peptide Receptor Radionuclide Therapy with [(177)Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions
por: del Olmo-García, Maria I., et al.
Publicado: (2022)

Nanostructures as Radionuclide Carriers in Auger Electron Therapy
por: Gharibkandi, Nasrin Abbasi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_df30i1r8ci9for3l43h92rmehp